Skip to main content
Premium Trial:

Request an Annual Quote

S&P Raises Life Tech Ratings to BBB+

NEW YORK (GenomeWeb News) – Standard & Poor's on Thursday raised Life Technologies' corporate credit rating and the issue-level rating on the firm's secured and unsecured debt to BBB+.

Both ratings were raised from prior BBB ratings. S&P said that the outlook for the Carlsbad, Calif.-based firm is stable.

"The upgrade reflects Life Technologies' track record of steadily reducing debt leverage since its large acquisition of Applied Biosystems in 2008, which brought leverage to 3.6x on a pro forma basis," S&P's credit analyst Rivka Gertzulin said in a statement.

The financial services company said that the investment grade rating assumes that the credit metrics will stay in the range appropriate for its "intermediate" financial risk profile, and added that it sees Life Tech's business risk profile as "satisfactory."

The company has a "well-established, diverse product portfolio, high rate of customer retention, non-cyclical demand, strong operating margins, and a high proportion of recurring revenues," S&P noted. It cautioned, though, that uncertainty around government funding for scientific research and weakness in the European economy remain challenges for Life Tech.

Revenue growth is anticipated to be in the low-single digits during the next two years, driven in the near-term by the launch of "its new gene sequencing machine," S&P said, an apparent reference to Life Tech's Ion Torrent desktop sequencers.

Debt leverage is expected to continue declining "moderately" during the next two years even as the company is expected to use half of its free cash flow for share repurchases. Acquisitions should continue to be moderate, S&P said.

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.